A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV
Phase 3
Completed
- Conditions
- HIV InfectionsChickenpox
- Registration Number
- NCT00002358
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.
- Detailed Description
Any physician qualified to treat pediatric AIDS patients may enroll patients in this study.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Bristol - Myers Squibb Co
🇺🇸Wallingford, Connecticut, United States